CN103193860B - Tanshinone compound, preparation method and its usage - Google Patents
Tanshinone compound, preparation method and its usage Download PDFInfo
- Publication number
- CN103193860B CN103193860B CN201310075156.1A CN201310075156A CN103193860B CN 103193860 B CN103193860 B CN 103193860B CN 201310075156 A CN201310075156 A CN 201310075156A CN 103193860 B CN103193860 B CN 103193860B
- Authority
- CN
- China
- Prior art keywords
- phenanthro
- dioxo
- hydrogen
- trimethylammonium
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 title claims abstract description 64
- -1 Tanshinone compound Chemical class 0.000 title claims abstract description 56
- 229930183118 Tanshinone Natural products 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 38
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 38
- 238000006243 chemical reaction Methods 0.000 claims description 133
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 238000010898 silica gel chromatography Methods 0.000 claims description 40
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims description 36
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 35
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 26
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 150000002240 furans Chemical class 0.000 claims description 20
- 239000011734 sodium Substances 0.000 claims description 20
- 229910052708 sodium Inorganic materials 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 15
- 238000005481 NMR spectroscopy Methods 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 8
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000005457 ice water Substances 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 5
- 239000012286 potassium permanganate Substances 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 229940047670 sodium acrylate Drugs 0.000 claims description 3
- 239000004324 sodium propionate Substances 0.000 claims description 3
- 229960003212 sodium propionate Drugs 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 abstract description 21
- 102000001307 androgen receptors Human genes 0.000 abstract description 20
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 12
- 206010000496 acne Diseases 0.000 abstract description 6
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 5
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000021595 spermatogenesis Effects 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 18
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 239000000376 reactant Substances 0.000 description 15
- 239000000051 antiandrogen Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 13
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 13
- 239000003098 androgen Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 159000000000 sodium salts Chemical class 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 9
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- 230000002280 anti-androgenic effect Effects 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 7
- 229960000997 bicalutamide Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000010189 synthetic method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 5
- 0 CC1(C)c2ccc(-c([o]cc3*)c3C(C3=O)=O)c3c2CCC1 Chemical compound CC1(C)c2ccc(-c([o]cc3*)c3C(C3=O)=O)c3c2CCC1 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 5
- 229960002074 flutamide Drugs 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 206010020112 Hirsutism Diseases 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000001548 androgenic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 3
- 206010021929 Infertility male Diseases 0.000 description 3
- 208000007466 Male Infertility Diseases 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 239000003936 androgen receptor antagonist Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- VIRPUNZTLGQDDV-UHFFFAOYSA-N chloro propanoate Chemical compound CCC(=O)OCl VIRPUNZTLGQDDV-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910000474 mercury oxide Inorganic materials 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101150029129 AR gene Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229940124011 Androgen receptor agonist Drugs 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010069921 Anti-androgen withdrawal syndrome Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BRHCKAYJGSHUFP-UHFFFAOYSA-N CC(C)(CCC1)c(cc2)c1c(C1=O)c2-c([o]c(CC(OC)=O)c2C)c2C1=O Chemical compound CC(C)(CCC1)c(cc2)c1c(C1=O)c2-c([o]c(CC(OC)=O)c2C)c2C1=O BRHCKAYJGSHUFP-UHFFFAOYSA-N 0.000 description 1
- JCCLNNIRESOKPN-UHFFFAOYSA-N CC1(C)c2ccc(-c([o]c(CCC(O)=O)c3C)c3C(C3=O)=O)c3c2CCC1 Chemical compound CC1(C)c2ccc(-c([o]c(CCC(O)=O)c3C)c3C(C3=O)=O)c3c2CCC1 JCCLNNIRESOKPN-UHFFFAOYSA-N 0.000 description 1
- BNAJDMBDZINFJZ-UHFFFAOYSA-N CC1(C)c2ccc(-c([o]cc3COC(C)=O)c3C(C3O)=O)c3c2CCC1 Chemical compound CC1(C)c2ccc(-c([o]cc3COC(C)=O)c3C(C3O)=O)c3c2CCC1 BNAJDMBDZINFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108700020473 Cyclic AMP Receptor Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- JEAVBVKAYUCPAQ-UHFFFAOYSA-N ethyl 2-chloropropanoate Chemical compound CCOC(=O)C(C)Cl JEAVBVKAYUCPAQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Tanshinone compound of the present invention, preparation method and its usage, relate to field of pharmaceutical chemistry technology.Tanshinone compound, has the Compound I or II of following general structure:
or
; This type of purposes includes but not limited to be used as antitumor drug, be particularly useful for treatment prostate cancer and bladder cancer, with induced androgen receptor antagonistic activity in the patient having the illness relevant with male sex hormone patient, with male sex hormone have about the uncontrolled spermatogenesis that includes but not limited to many illnesss, acne and wherein need Inhibit sperm to occur of the example of illness.
Description
Technical field
The present invention relates to field of pharmaceutical chemistry technology, relate to some novel androgen antagonists by compound, containing pharmaceutical dosage form and the using method thereof, particularly tanshinone compound and uses thereof of described compound.
Background technology
In elderly men, numerous disease is relevant with Serum Testosterone Levels.With advancing age, in health, androgenic level can decline the male sex, reduces, the phenomenons such as sexual disorder along with muscle in body.On the contrary, in body, androgen levels is too high can bring some other disease equally, if hyperplasia of prostate and prostate cancer are exactly androgen-dependent disorders, also have some other disease relevant with androgen levels, stop containing androgen receptor in body skin hair, these acceptors of some people are comparatively responsive to male sex hormone, cause alopecia, in young adult's skin, androgen receptor is comparatively responsive, causes the growth etc. that powder does not sting.
Utilize androgen antagonist can treat the above-mentioned disease relevant with male sex hormone.Selectivity androgen antagonist is the research direction in this field, the androgen receptor of human body Different Organs is had to the target of this pass medicinal design of optionally androgen antagonist.Adopt anti-androgen therapy necessary often to above-mentioned disease.
Androgen receptor (Androgenreceptor, AR) be that a class extensively distributes in vivo, the nuclear factor superfamily member of Ligand activation, Chang and Lubean etc. are respectively at different experiments room successful clone AR gene (Science, 1988,240 (4850): 324-326., Science, 1988,240 (4850): 327-330).Androgen receptor prostaticly growing, function maintain and prostate cancer generation development and worsen in transfer process and all play very important effect.Prostate cancer is the modal male malignancy of European and American developed countries, accounts for the 2nd of the male cancer cause of the death.Within 2012, the U.S. is diagnosed with about 241740 people of prostate cancer, and about 28170 people are because suffering from prostate cancer death (SiegelR, et.al., CancerJClin2012; 62 (1): 10-29(2012)).The morbidity of current China prostate cancer is lower than Hesperian sickness rate, but China presents the trend risen rapidly in recent years.Male sex PCa sickness rate in Beijing rises to the growths by 200.5% in 16.62/10 ten thousand, 9 years of 2010 by 5.53/10 ten thousand of calendar year 2001, increases by 9.2% every year, in front ten large male malignancy, occupies the 5th.Can estimate thus, along with significantly rising fast of sickness rate, prostate cancer will become one of kinds of tumor of threat China men's health gradually.Some anti-androgen receptor medicines, as flutamide (flutamide, HF) and bicalutamide (bicalutamide) have been widely used in clinical treatment prostate cancer.(Crawfordetal., NewEngl.J.Med., 321,419-424 (1989)), but this medicine has a lot of side effect (Neumannetal., J.Clin.Oncol., Isosorbide-5-Nitrae 1-65 (1982)).Flutamide and bicalutamide are nonsteroidal anti-androgen receptor medicine, although be widely used in treatment prostate cancer, some anti-androgen receptor medicines can may cause " the antiandrogen withdrawal syndrome " (Miyamotoetal. as androgen receptor agonist, Proc.Natl.Acad.Sci.USA, 95,7379-7384 (1998)).It is generally acknowledged that androgen receptor gene is undergone mutation at present to " flutamide removes syndrome ", the target gene of the catabolite activator androgen receptor of flutamide, as prostate specific antigen (PSA), cause PSA to rise, after stopping, PSA declines.In fact, the process LAN of the sub-ARA70 of another androgen receptor assisted activation can make AR be activated by androgen receptor antagonist, thus cause with the recurrence of the prostate cancer of androgen receptor antagonist method treatment, even develop into non-androgen-dependent prostate cancer (Yehetal., TheLancet, 349,852-853 (1997)), therefore in the urgent need to developing more effective androgen antagonist new drug, advanced prostate cancer is used for the treatment of.
In new drug development design process, by improving its biological activity to the structural modification of natural compounds with transformation, improving the targeting for the treatment of, reducing research emphasis and difficult point that drug toxicity is new drug development.From Chinese traditional Chinese medicine treasure-house, wherein extract effective monomer find that active ingredient is lead compound, then carry out structure of modification, be the some effective of new drug development, about have the clinical application about half to be natural product and derivative thereof at present.
The red sage root is the root and rhizome of the lip section plant red sage root (SalviamiltiorrhizaBunge), begin to be loaded in Shennong's Herbal, it is the common traditional Chinese medicine of China, there is many-sided curative effect clinically, as effects such as promoting blood flow to regulate menstruation, antipruritic, the tranquilizing by nourishing the hearts of easing pain, be mainly used in the diseases such as treatment is cardiovascular, hypertension, cerebral ischemia at present, its primary chemical activeconstituents is o-quinone structure tanshinone compound.It is active that we have found that this compounds has good anti-androgen receptor, (Xu Defeng, Zhang Chuanxiang, Ji Yejun, tanshinone compound and application thereof, Chinese patent: CN102127037A), the present invention is that parent compound carries out structural modification and synthesizes a series of tanshinone compound on this basis with TANSHINONES, can be used as anti-androgen receptor medicine and be used for the treatment of the disease relevant with male sex hormone such as prostate cancer, hyperplasia of prostate, acne, alopecia, comedo, hirsutism.The invention still further relates to the application of tanshinone compound as medicine, using the effective constituent of tanshinone compound as androgen receptor antagonist, independent application or share or with the combinations such as acceptable vehicle, conventionally make oral preparation or parenteral type is used for the treatment of and male hormone relative disease.
The present invention refers to be used for the treatment of human and animal's disease or physiologic derangement, especially for medicine or the medicine composition for the treatment of human diseases or physiologic derangement class, these medicines or medicine composition contain with the compound of following compound formula or the salt of composition, or suitable pharmaceutically acceptable carrier or diluent, these human diseasess or physiologic derangement comprise the prostate cancer human diseases relevant to androgen receptor with other and are not suitable for symptom, as hyperplasia of prostate, acne, alopecia, hirsutism, muscle depletion, gonad function is weak, cholesterol is too high, male sterility, male's sexual is bad, anaemia, fat, these medicines or medicine composition also can have other purposes, disease as relevant with male sex hormone in male contraception etc.
Summary of the invention
The object of the invention is to overcome deficiency of the prior art, find the active high class anti-androgen receptor compound of a class, a kind of tanshinone compound is provided, can be used as anti-androgen receptor medicine and be used for the treatment of the disease relevant to male sex hormone, can be used for treatment prostate cancer, as hyperplasia of prostate, acne, alopecia, hirsutism, muscle depletion, gonad function is weak, cholesterol is too high, male sterility, the diseases such as male's sexual is bad, anaemia, obesity.
Main purpose of the present invention is to provide chemical structure and the medical usage of this compounds.
Tanshinone compound, has the Compound I or II of following general structure:
Wherein R is CHO, Br, NO
2, OCH
3, CH
2oOCH
3, COCH
3, C
1-C
3carboxylic acid and sodium salt, carboxylicesters, vinyl cyanide, vinylformic acid and sodium salt or acrylate etc.
The purposes of tanshinone compound, for the preparation of anti-androgen receptor medicine.Be used for the treatment of the disease relevant to male sex hormone, can be used for treatment prostate cancer, as hyperplasia of prostate, acne, alopecia, hirsutism, muscle depletion, gonad function is weak, cholesterol is too high, male sterility, the diseases such as male's sexual is bad, anaemia, obesity.
Compound involved in the present invention is by following route synthetic method one:
The preparation method of tanshinone compound, step specific as follows: tanshinone IIA and Vilsmeier reagent (dimethyl formamide and phosphorus oxychloride) react prepares aldehyde compound, potassium permanganate can be adopted under phase-transfer catalyst effect to generate carboxylic acid, obtain carboxylicesters through esterification, react to sodium ethylate and generate corresponding sodium salt.
The preparation method of tanshinone compound, specifically carries out in accordance with the following steps:
(1) in reaction flask, add tanshinone IIA (1), dimethyl formamide (DMF), phosphorus oxychloride, 1-5 hour is reacted at 30-100 DEG C, reaction solution is poured in frozen water, has yellow mercury oxide, filters, washing, dry crude product, crude product obtains tanshinone IIA formaldehyde (2) through silica gel column chromatography, and wherein the mol ratio of reactant tanshinone IIA, dimethyl formamide (DMF), phosphorus oxychloride is 1:2-15:2-25, temperature of reaction 30-100 DEG C, reaction 1-5 hour.
(2) in reaction flask, 2 are added, acetone, Tetrabutyl amonium bromide and mass concentration are the potassium permanganate solution of 5%, at 20-80 DEG C, reaction 10-25 hour, solids removed by filtration, filtrate regulates PH=2 with hydrochloric acid, precipitation is had to generate, filter, dry, 1 is obtained with silica gel column chromatography, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furyl-2-formic acid (3), wherein reactant tanshinone IIA (1), Tetrabutyl amonium bromide, the potassium permanganate of 5%, acetone mol ratio is 1:0.05-0.2:2-5:5-25, temperature of reaction 20-80 DEG C, reaction 10-25 hour.
(3) in reaction flask, 1 is added, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furyl-2-formic acid (3), dehydrated alcohol, 10% alcohol sodium solution, namely solid is had to separate out, filter to obtain sodium salt 1, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furyl-2-sodium formiate (4), wherein 1, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furyl-2-formic acid (3), dehydrated alcohol, 10% alcohol sodium solution mol ratio is 1:2-5:2-15:0.95-1.25, temperature of reaction 20-80 DEG C, reaction 1-3 hour.
(4) 1,6,6-trimethylammonium-6 is added in reaction flask, 7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid (3), dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride, at room temperature react 2-12 hour, solids removed by filtration, obtains 1 with silica gel column chromatography, and 6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid ester compound (5).Wherein reactant 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid (3), dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride equimolar ratio be 1:1-3:0.1-0.25:1-10:5-50, temperature of reaction 0-80 DEG C, reaction 1-12 hour.
Compound involved in the present invention is by following route synthetic method two
The preparation method of tanshinone compound, specifically carries out in accordance with the following steps:
Tanshinone IIA and nitration mixture (acetic acid and nitric acid) carry out nitration reaction and obtain 2-nitro-1, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans (6), tanshinone IIA (1) is added in reaction flask, diacetyl oxide, glacial acetic acid and nitrosonitric acid, react after 1-8 hour and stop pouring in frozen water, separate out a large amount of yellow solid, filter, washing, dry, obtain nitro-compound 2-nitro-1, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans (6), wherein reactant tanshinone IIA (1), diacetyl oxide, glacial acetic acid and nitrosonitric acid mol ratio are 1:1-2:2-5:2-5, temperature of reaction-10 is to 0 DEG C, reaction 1-12 hour.
Tanshinone IIA and N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS) react and generate corresponding halogenated product 2-halogen-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (6).
In reaction flask, add tanshinone IIA (1), acetic acid, N-halosuccinimides, acetic acid, at temperature of reaction-10 is to 20 DEG C, reacts 2-10 hour, adds water, 2-halogen-1,6,6-trimethylammonium-6 is obtained with dichloromethane extraction, 7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (7), wherein reactant tanshinone IIA (1), N-halosuccinimides, acetic acid mol ratio are 1:1-3:2-15, and temperature of reaction-10, to 20 DEG C, reacts 2-10 hour.
Tanshinone IIA generates acetyl compound 8 with excess acetyl chloride under catalyst action.
Tanshinone IIA (1), pyridine, Acetyl Chloride 98Min. is added in reaction flask; react 1-5 hour at 20-100 DEG C after, reaction solution is poured in frozen water; filter; washing, dry crude product, crude product obtains acetyl compound 2-ethanoyl-1 through silica gel column chromatography; 6; 6-trimethylammonium-6,7,8; 9; 10,11-six hydrogen-10,11-dioxo phenanthro-[1; 2-b] furans (8); wherein reactant tanshinone IIA (1), pyridine, Acetyl Chloride 98Min. mol ratio are 1:2-25:1-5, temperature of reaction 20 to 100 DEG C, reaction 1-5 hour.
Compound involved in the present invention is by following route synthetic method three
Method three of the present invention step specific as follows:
Tanshinone IIA is oxidized and generates aldehyde compound under tin anhydride catalysis, carries out reduction oxy-compound respectively, generates acrylic compounds, carry out esterification obtain corresponding acrylic ester compound to alcohol with propanedioic acid under pyridine and piperidines catalysis.
(1) in reaction flask, add tanshinone IIA (1), tin anhydride, dioxane, heating reflux reaction 5-24 hour, filter, concentrated, obtain 6,6-dimethyl-6 with silica gel column chromatography, 7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-1-formaldehyde (9), wherein reactant tanshinone IIA (1), tin anhydride, dioxane mol ratio are 1:0.5-2.5:3-25, temperature of reaction 40 to 110 DEG C, reaction 5-24 hour.
(2) in reaction flask, 6 are added, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans-1-formaldehyde (9), methyl alcohol, methylene dichloride, sodium borohydride, 10-120 minute is reacted at-10 to 5 DEG C, be extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, 1-(methylol is obtained with silica gel column chromatography)-6, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans (10), wherein 6, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans-1-formaldehyde (9), methyl alcohol, methylene dichloride, sodium borohydride mol ratio is 1:2-10:2-5:1-2.5, temperature of reaction-10 is to 5 DEG C, reaction 10-120 minute.
(3) in reaction flask, 1-(methylol is added)-6, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans (10), methylene dichloride, triethylamine, diacetyl oxide, reaction response 1-3 hour at-10 to 5 DEG C, be extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, 6 are obtained with silica gel column chromatography, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans-2-methyl acetic acid ester (11), wherein 1-(methylol)-6, 6-dimethyl-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans (10), methylene dichloride, triethylamine, diacetyl oxide mol ratio is 1:2-10:1-2.5:1-2.5, temperature of reaction-10 is to 5 DEG C, reaction 1-3 hour.
Compound involved in the present invention is by following route synthetic method four
Method four of the present invention step specific as follows:
TANSHINONES aldehyde compound carries out selective reduction reduction reaction and generates oxy-compound or ether compound respectively, and oxy-compound and acetic anhydride generate corresponding ester compound.
(1) in reaction flask, add tanshinone IIA formaldehyde (2), methyl alcohol, methylene dichloride, sodium borohydride, at-10 to 5 DEG C, reaction times 10-60 minute, be extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration obtains compound 12, and wherein the mol ratio of tanshinone IIA formaldehyde (2), methyl alcohol, methylene dichloride, sodium borohydride is 1:10-100:10-100:1-2.5, temperature of reaction-10 to 5 DEG C, reaction times 10-60 minute.
(2) in reaction flask, compound 12, methylene dichloride, diacetyl oxide is added, at-10 to 5 DEG C, reaction 1-3 hour, be extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, compound 13 is obtained with silica gel column chromatography, wherein the mol ratio of compound 12, methylene dichloride, diacetyl oxide is 1:10-100:1-2.5, temperature of reaction-10 to 5 DEG C, reaction times 1-3 hour.
(3) in reaction flask, add tanshinone IIA formaldehyde (2), 10%(mass concentration) palladium carbon, methyl alcohol, at room temperature hydrogenation reaction 20-24 hour, filter palladium carbon, vacuum concentration, target compound 14 is obtained with silica gel column chromatography, wherein the mol ratio of compound tanshinone IIA formaldehyde (2), 10% palladium carbon, methyl alcohol, hydrogen is 1:0.01-0.2:10-100:1:5, temperature of reaction 10 to 40 DEG C, reaction times 10-36 hour.
Compound involved in the present invention is by following route synthetic method five
Method five of the present invention step specific as follows:
TANSHINONES carbonyl compound, under pyridine and piperidines catalysis, carry out decarboxylation fertilizer with propanedioic acid should generation acrylic compounds, then carries out esterification to alcohol and obtain corresponding acrylic ester compound.
(1) in reaction flask, compound 15, benzene, propanedioic acid, pyridine is added, reflux divides water, and reaction 8-20 hour, removes solvent under reduced pressure, the aqueous sodium carbonate of 5% is added in residue, filter, filtrate transfers in about PH=2 with concentrated hydrochloric acid, filters, carboxylic acid cpd 16 is obtained with silica gel column chromatography, wherein compound 15, benzene, propanedioic acid, pyridine equimolar ratio are 1:10-30:1-5:0.2-2.5, temperature of reaction 40-100 DEG C, reaction 8-20 hour.
(2) in reaction flask, add carboxylic acid cpd 16, dehydrated alcohol, 10%(mass concentration) alcohol sodium solution, namely solid is had to separate out, filter to obtain sodium salt 18, wherein reactant 16, dehydrated alcohol, 10% alcohol sodium solution mol ratio are 1:2-5:2-5:0.95-1.25, temperature of reaction 20-80 DEG C, reaction 1-3 hour.
(3) carboxylic acid cpd 16, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride is added in reaction flask, at room temperature react 2-12 hour, solids removed by filtration, obtains ester cpds 17 with silica gel column chromatography.Wherein reactant 16, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride equimolar ratio are 1:1-3:0.1-0.25:1-3:5-50, temperature of reaction 0-80 DEG C, reaction 1-12 hour.
Compound involved in the present invention is by following route synthetic method six
Method six of the present invention step specific as follows:
TANSHINONES is reacted to ethyl chloroacetate or chloropropionic acid ethyl ester and is generated corresponding carboxylic acid ester compound under zirconium chloride catalysis, then hydrolysis generates corresponding carboxylic acid cpd in the basic conditions, reacts generate corresponding sodium salt to sodium ethylate.
(1) in reaction flask, add tanshinone IIA (1), methylene dichloride, zirconium tetrachloride, ethyl chloroacetate (or chloropropionate), return stirring reaction 2-10 hour, solids removed by filtration, filter vacuum concentrates, residual silica gel column chromatography obtains compound 19, wherein tanshinone IIA (1), methylene dichloride, zirconium tetrachloride, ethyl chloroacetate (or chloropropionate) mol ratio are 1:15-50:2-5:1-3, temperature of reaction 20-80 DEG C, reaction 2-10 hour.
(2) in reaction flask, add to obtain compound 19,5%(mass concentration) aqueous sodium hydroxide solution, reflux 1-4 hour, filters, and filtrate regulates about PH2 with concentrated hydrochloric acid, separates out solid, filters, dry, obtains carboxylic acid cpd 20 with silica gel column chromatography,
(3) wherein reactant compound 19 and 5%(mass concentration) aqueous sodium hydroxide solution mol ratio be 1:1-2.5, temperature of reaction 30-110 DEG C, reaction 1-4 hour.
(4) in reaction flask, add carboxylic acid cpd 20, dehydrated alcohol, 10% alcohol sodium solution, namely solid is had to separate out, filter to obtain sodium salt 21, wherein reactant 20, dehydrated alcohol, 10%(mass concentration) alcohol sodium solution mol ratio is 1:2-5:2-5:0.95-1.25, temperature of reaction 20-80 DEG C, reaction 1-3 hour.
(5) carboxylic acid cpd 20, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride is added in reaction flask, at room temperature react 2-12 hour, solids removed by filtration, obtains ester cpds 22 with silica gel column chromatography.Wherein reactant 20, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride equimolar ratio are 1:1-3:0.1-0.25:1-3:5-50, temperature of reaction 0-80 DEG C, reaction 1-12 hour.
Compound involved in the present invention is by following route synthetic method seven
Method seven of the present invention step specific as follows:
TANSHINONES is reacted with butyryl oxide and is generated butyric acid compound under zirconium chloride catalysis, then reacts with alcohol and generate carboxylic acid ester compound, reacts generate corresponding sodium salt to sodium ethylate.
(1) in reaction flask, add tanshinone IIA (1), methylene dichloride, zirconium tetrachloride, Succinic anhydried, return stirring reaction 2-12 hour, solids removed by filtration, filter vacuum concentrates, residual silica gel column chromatography obtains carboxylic acid cpd 23, wherein reactant tanshinone IIA (1), methylene dichloride, zirconium tetrachloride, Succinic anhydried mol ratio are 1:15-100:2-5:1-1.5, temperature of reaction 20-80 DEG C, reaction 2-12 hour.
(2) in reaction flask, add carboxylic acid cpd 23, dehydrated alcohol, 10%(mass concentration) alcohol sodium solution, namely solid is had to separate out, filter to obtain sodium salt 24, wherein reactant 23, dehydrated alcohol, 10% alcohol sodium solution mol ratio are 1:2-5:2-5:0.95-1.25, temperature of reaction 20-80 DEG C, reaction 1-3 hour.
(3) carboxylic acid cpd 23, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride is added in reaction flask, at room temperature react 2-12 hour, solids removed by filtration, obtains ester cpds 25 with silica gel column chromatography.Wherein reactant 23, dicyclohexylcarbodiimide (DCC), DMAP (DMAP), absolute alcohol, methylene dichloride equimolar ratio are 1:1-3:0.1-0.25:1-3:5-50, temperature of reaction 0-80 DEG C, reaction 1-12 hour.
Advantage of the present invention:
AR has multiple hypotype, perfect form (fAR) and spliced variants type androgen receptor (ARVs), wherein spliced variants type androgen receptor (ARVs) is that advanced prostate cancer is distinctive, we all effectively suppress perfect form (fAR) and spliced variants type androgen receptor (ARVs) by the tanshinone compound of invention, can be used for the treatment of advanced prostate cancer.Compared with existing clinical medicine bicalutamide, perfect form (fAR) can only be suppressed, spliced variants type androgen receptor (ARVs) can not be suppressed, cause bicalutamide invalid to advanced prostate cancer, the present invention overcomes the deficiency of upper existing androgen antagonist medicine, can be used for treating advanced prostate cancer.
Accompanying drawing explanation
Fig. 1 is the relative Developing restraint ability of compound to LNCaP cell; Fig. 2 is the relative Developing restraint ability of compound to CWR22RV1 cell.
Embodiment
The present invention relates to the medicine of tanshinone compound, its structural formula of the compound comprised is as follows:
Example one, 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-2-formaldehyde (Tan-001)
Tanshinone IIA (2.94g is added in reaction flask, 19mmol), 50ml dimethyl formamide (DMF), stirred at ambient temperature drips 7ml phosphorus oxychloride, at 70-80 DEG C, react reaction solution after 2 hours pours in the frozen water of 750ml, there is yellow mercury oxide, filter, washing, dry crude product, crude product obtains through silica gel column chromatography, productive rate 67%
1h-NMR (300MHz, (CDCl
3)), δ: 9.86 (s, 1H), 8.80 (d, J=6.3Hz, 1H), 7.71 (d, J=6.3Hz, 1H), 3.21 (m, 2H), 2.65 (s, 3H), 1.78-1.82 (m, 2H), 1.65-1.69 (m, 2H), 1.42 (s, 6H).
Bromo-10,11-dioxo-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen phenanthro-[1, the 2-b] furans (Tan-002) of example two, 2-
In reaction flask, add tanshinone IIA (1.47g, 5mmol), acetic acid 80ml, slowly drip N-bromosuccinimide NBS(1.07g, solution 6mmol) in 25ml acetic acid, room temperature reaction 6 hours, adds water, with dichloromethane extraction, combining extraction liquid, washes with water successively, and sodium sulfite aqueous solution washs, saturated sodium-chloride water solution washs, anhydrous sodium sulfate drying, obtains red solid with silica gel column chromatography
1h-NMR (300MHz, (CDCl
3)), δ: 7.68 (d, J=7.9Hz, 1H), 7.53(d, J=7.9Hz, 1H), 3.19 (m, 2H), 2.21 (s, 3H), 1.77-1.83 (m, 2H), 1.64-1.71 (m, 2H), 1.31 (s, 6H).
Chloro-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-003) of example three, 2-
Reaction, with example two, replaces NBS with N-chlorosuccinimide (NCS), obtains target product,
1h-NMR (300MHz, (CDCl
3), δ: 7.69 (d, J=7.2Hz, 1H), 7.56 (d, J=7.2Hz, 1H), 3.19 (m, 2H), 2.23 (s, 3H), 1.77-1.85 (m, 2H), 1.64-1.75 (m, 2H), 1.31 (s, 6H).
Iodo-10,11-dioxo-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen phenanthro-[1, the 2-b] furans (Tan-004) of example four, 2-
In reaction flask, add tanshinone IIA (59mg, 0.2mmol), methylene dichloride 20ml, be cooled to-40 DEG C, slowly drip N-iodosuccinimide NIS(67.2g, 0.6mmol) 5ml dichloromethane solution ,-40 DEG C of reactions 6 hours, add water, with dichloromethane extraction, combining extraction liquid, wash with water successively, sodium sulfite aqueous solution washs, saturated sodium-chloride water solution washs, and anhydrous sodium sulfate drying, obtains red solid with silica gel column chromatography.
1H-NMR(300MHz,(CDCl
3),δ:7.63(d,J=7.5Hz,1H),7.55(d,J=7.5Hz,1H),3.18(m,2H),2.23(s,3H),1.78-1.86(m,2H),1.65-1.72(m,2H),1.32(s,6H)。
Example five, 2-nitro-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-005)
Tanshinone IIA (59mg is added in reaction flask, 0.2mmol), 30ml diacetyl oxide, be cooled to less than 0 DEG C with ice-water bath, add in the nitration mixture that glacial acetic acid (1.4g) and nitrosonitric acid (1.5g) make, react stopped reaction after 3-4 hour, reaction mixture is poured in frozen water, separate out a large amount of yellow solid, filtration, washing, drying, obtain target compound with silica gel column chromatography, yield 68%
1h-NMR (300MHz, (CDCl
3)), δ: 7.79 (d, J=7.2Hz, 1H), 7.74 (d, J=7.2Hz, 1H), 3.21 (m, 2H), 2.76 (s, 3H), 1.78-1.86 (m, 2H), 1.66-1.73 (m, 2H), 1.32 (s, 6H).
Example six, 2-(methylol)-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-006)
Tan-001(129mg is added in reaction flask, 0.4mmol), 15ml methyl alcohol and 10ml methylene dichloride, be cooled to less than 0 DEG C with ice-water bath, add sodium borohydride (30mg, 0.81mmol), under ice bath, stirring reaction 15-20 minute, is extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, target compound is obtained, yield 75% with silica gel column chromatography
1h-NMR (300MHz, (CDCl
3)), δ: 7.60 (d, J=6.8Hz, 1H), 7.51 (d, J=6.8Hz, 1H), 4.68 (s, 2H), 3.16 (m, 2H), 2.26 (s, 3H), 1.76-1.85 (m, 2H), 1.63-1.76 (m, 2H), 1.31 (s, 6H).
Example seven, 2-ethanoyl-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-007)
In reaction flask, add tanshinone IIA (2.94g, 19mmol), 120ml pyridine, stirred at ambient temperature drips 8ml Acetyl Chloride 98Min., at 70-80 DEG C, react reaction solution after 2 hours pours in the frozen water of 750ml, filters, washing, dry crude product, crude product obtains target compound through silica gel column chromatography, productive rate 73%
1h-NMR (300MHz, (CDCl
3)), δ:, 8.09 (d, J=7.2Hz, 1H), 7.63 (d, J=7.2Hz, 1H), 3.19 (m, 2H), 2.89 (s, 3H), 2.35 (s, 3H), 1.76-1.85 (m, 2H), 1.66-1.78 (m, 2H), 1.38 (s, 6H)
Example eight, 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans is muttered-2-methyl acetic acid ester (Tan-008)
Tan-006(130mg is added in reaction flask, 0.4mmol), 25ml methylene dichloride, be cooled to less than 0 DEG C with ice-water bath, drip diacetyl oxide (1ml), stirring reaction 1-1.5 hour under ice bath, be extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, obtains target compound with silica gel column chromatography, yield 86%
1h-NMR (300MHz, (CDCl
3), δ: 7.61 (d, J=7.2Hz, 1H), 7.54 (d, J=7.2Hz, 1H), 5.07 (s, 2H), 3.14 (m, 2H), 2.28 (s, 3H), 2.02 (s, 3H), 1.78 (m, 2H), 1.63 (m, 2H), 1.29 (s, 6H).
Example nine, 2-(methoxyl group)-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-009)
In reaction flask, add Tan-001(260mg, 0.8mmol), 10% palladium carbon (30mg), 50ml methyl alcohol, at room temperature hydrogenation reaction 20-24 hour, filter palladium carbon, vacuum concentration, obtains target compound with silica gel column chromatography, yield 29%,
1h-NMR (300MHz, (CDCl
3), δ: 7.67 (m, 2H), 4.08 (s, 3H), 3.18 (m, 2H), 2.39 (s, 3H), 1.76-1.79 (m, 2H), 1.61-1.65 (m, 2H), 1.29 (s, 6H).
Example ten, 6,6-dimethyl-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans is muttered-1-formaldehyde (Tan-010)
In reaction flask, add tanshinone IIA (200mg, 0.68mmol), tin anhydride (225mg, 2.03mmol), 25ml dioxane, heating reflux reaction 10-12 hour, filter, concentrated, obtain target compound Tan-010 with silica gel column chromatography, yield 33%,
1h-NMR (300MHz, (CDCl
3), δ: 10.33 (s, 1H), 8.01 (d, J=7.5Hz, 1H), 7.69 (d, J=7.5Hz, 1H), 3.23 (m, 2H), 1.76-1.88 (m, 2H), 1.63-1.73 (m, 2H), 1.32 (s, 6H).
Example 11,1-(methylol)-6,6-dimethyl-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans (Tan-011)
Tan-010(125mg is added in reaction flask, 0.4mmol), 10ml methyl alcohol and 20ml methylene dichloride, be cooled to less than 0 DEG C with ice-water bath, add sodium borohydride (29mg, 0.80mmol), under ice bath, stirring reaction 30-40 minute, is extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, target compound is obtained, yield 67% with silica gel column chromatography
1h-NMR (300MHz, (CDCl
3)) δ: 7.68 (d, J=7.8Hz, 1H), 7.57 (d, J=7.2Hz, 1H), 7.37 (s, 1H), 4.25 (s, 2H), 3.19 (m, 2H), 1.78-1.83 (m, 2H), 1.64-1.72 (m, 2H), 1.31 (s, 6H).
Example 12,6,6-dimethyl-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-2-methyl acetic acid ester (Tan-012)
Tan-011(125mg is added in reaction flask, 0.4mmol), 20ml methylene dichloride, be cooled to less than 0 DEG C with ice-water bath, drip 2ml triethylamine, then 1ml diacetyl oxide is dripped, in ice bath, stirring reaction 1 hour, is extracted with ethyl acetate, washing, anhydrous sodium sulfate drying, vacuum concentration, target compound is obtained, yield 83% with silica gel column chromatography
1h-NMR (300MHz, (CDCl
3)) δ: 7.59 (d, J=6.0Hz, 1H), 7.55 (d, J=6.0Hz, 1H), 7.473 (s, 2H), 5.24 (s, 2H), 3.19 (t, 2H), 2.11 (s, 3H), 1.76-1.81 (m, 2H), 1.64-1.67 (m, 2H), 1.31 (s, 6H).
Example 13,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid (Tan-013)
Tan-001(258mg is added in reaction flask, 0.8mmol), 40ml acetone, Tetrabutyl amonium bromide (15mg), be cooled to less than 0 DEG C with ice-water bath, drip concentration be 5% potassium permanganate solution 15ml, at room temperature react 15-20 hour, solids removed by filtration, filtrate regulates PH=2 with hydrochloric acid, has precipitation to generate, filtration, drying, target compound is obtained, yield 46% with silica gel column chromatography
1h-NMR (400MHz, (CDCl
3), δ: 9.89 (s, 1H), 7.99 (d, J=7.8Hz, 1H), 7.67 (d, J=7.8HZ, 1H), 2.97 (t, 7.8HZ, 7.8Hz, 2H), 2.68 (s, 3H), 2.11 (t, J=7.8HZ, 7.8HZ, 2H), 1.81 (m, 2H), 1.37 (s, 6H).
Example 14,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-methyl acetate (Tan-014)
Tan-013(100mg is added in reaction flask, 0.3mmol), dicyclohexylcarbodiimide (DCC) ((80mg, 0.38mmol), (DMAP (DMAP) (10mg), 1ml anhydrous methanol, 25ml methylene dichloride, at room temperature react 4-6 hour, solids removed by filtration, target compound is obtained, yield 82%, ESI-MS [M with silica gel column chromatography
+] (m/z): 352.13.
Example 15,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-ethyl formate (Tan-015)
Reaction, with example 15, replaces anhydrous methanol with dehydrated alcohol, obtains target product, yield 74%, ESI-MS [M
+] (m/z): 366.15.
Example 16,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium formiate (Tan-016)
Tan-013(300mg, 0.89mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 91%, ESI-MS [M
+] (m/z): 360.14.
Example 17,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-ethyl acetate (Tan-017)
Tanshinone IIA (1.47g is added in reaction flask, 5mmol), 75ml methylene dichloride, zirconium tetrachloride (1.2g, 5.2mmol), 3ml ethyl chloroacetate, return stirring reaction 4-6 hour, solids removed by filtration, filter vacuum concentrates, and residual silica gel column chromatography obtains target compound, yield 79%, ESI-MS [M
+] (m/z): 380.16.
Example 18,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-acetic acid (Tan-018)
Tan-017(760mg is added in reaction flask, 2mmol), the aqueous sodium hydroxide solution (150ml) of 5%, reflux 1-2 hour, stopped reaction, filter, filtrate regulates about PH2 with concentrated hydrochloric acid, separates out solid, filters, dry, target compound is obtained, yield 81%, ESI-MS [M with silica gel column chromatography
+] (m/z): 352.13.
Example 19,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-methyl acetate (Tan-019)
Reaction, with example 15, replaces Tan-013 with Tan-019, obtains target product, yield 84%, ESI-MS [M
+] (m/z): 366.15.
Example 20,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium acetate (Tan-020)
Tan-018(300mg, 0.85mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 89%, ESI-MS [M
+] (m/z): 374.11.
Example 21,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-ethyl propionate (Tan-021)
Tanshinone IIA (1.47g is added in reaction flask, 5mmol), 75ml methylene dichloride, zirconium tetrachloride (1.2g, 5.2mmol), 3ml chloropropionate, return stirring reaction 4-6 hour, solids removed by filtration, filter vacuum concentrates, and residual silica gel column chromatography obtains target compound, yield 63%, ESI-MS [M
+] (m/z): 394.18.
Example 22,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-propionic acid (Tan-022)
Tan-021(800mg is added in reaction flask, 2mmol), the aqueous sodium hydroxide solution (150ml) of 5%, reflux 1-2 hour, stopped reaction, filter, filtrate regulates about PH2 with concentrated hydrochloric acid, separates out solid, filters, dry, target compound is obtained, yield 72%, ESI-MS [M with silica gel column chromatography
+] (m/z): 366.15.
Example 23,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-methyl propionate (Tan-023)
Reaction, with example 15, replaces Tan-013 with Tan-021, obtains target product, yield 86%, ESI-MS [M
+] (m/z): 380.16.
Example 24,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium Propionate (Tan-024)
Tan-021(300mg, 0.82mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 88%, ESI-MS [M
+] (m/z): 388.13.
Example 25,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-butyric acid (Tan-025)
Tanshinone IIA (1.47g is added in reaction flask, 5mmol), 100ml methylene dichloride, zirconium tetrachloride (1.2g, 5.2mmol), Succinic anhydried (0.69g, 7.5mmol), return stirring reaction 4-6 hour, solids removed by filtration, filter vacuum concentrates, residual silica gel column chromatography obtains target compound, yield 75%, ESI-MS [M
+] (m/z): 380.16.
Example 26,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-methyl-butyrate (Tan-026)
Reaction, with example 15, replaces Tan-013 with Tan-025, obtains target product, yield 86%, ESI-MS [M
+] (m/z): 394.18.
Example 27,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-ethyl butyrate (Tan-027)
Reaction, with example 15, replaces Tan-013 with Tan-025, and dehydrated alcohol replaces anhydrous methanol, obtains target product, yield 83%, ESI-MS [M
+] (m/z): 408.19.
Example 28,1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium propanecarboxylate (Tan-028)
Tan-025(300mg, 0.79mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 89%, ESI-MS [M
+] (m/z): 402.14.
Example 29 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-vinylformic acid (Tan-029)
(Tan-001) (1.47g is added in reaction flask, 5mmol), 100ml benzene, propanedioic acid (1.2g, 5.2mmol), 10ml pyridine, reflux divides water, reaction 10-12 hour, remove solvent under reduced pressure, in residue, add the aqueous sodium carbonate of 5%, filter, filtrate transfers in about PH=2 with concentrated hydrochloric acid, filter, obtain target compound with silica gel column chromatography, yield 76%.
1H-NMR(300MHz,(DMSO-d
6),δ:12.56(s,1H),7.78-7.85(m,2H),7.51(d,1H),6.46(d,1H),3.09(m,2H),1.73(m,2H),1.73(m,2H),1.64(m,2H),2.37(s,3H),1.28(s,6H)。
Example 30 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-vinylformic acid formic acid (Tan-030)
Reaction, with example 15, replaces Tan-013 with Tan-029, obtains target product, yield 81%.
1H-NMR(300MHz,(CDCl
3),δ:7.78(d,1H),7.65(d,1H),7.49(d,H),6.42(d,1H),3.82(s,3H),2.92(m,2H),2.40(s,3H),2.20(m,2H),1.34(s,6H)。
Example 31 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-ethyl propenoate (Tan-031)
Reaction, with example 15, replaces Tan-013 with Tan-029, and dehydrated alcohol replaces anhydrous methanol, reacts to obtain target product, yield 85%.
1H-NMR(300MHz,(CDCl
3),δ:7.70(m,2H),7.46(d,1H),6.42(d,1H),5.39(s,1H),4.29(m,2H),3.29(m,2H),2.39(s,3H),1.79(m,2H),1.64(m,2H),1.27(m,3H),1.17(s,6H)。
Example 32 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-sodium acrylate (Tan-032)
Tan-029(300mg, 0.83mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 81%, ESI-MS [M
+] (m/z): 386.11.
Example 33 3-[(6,7,8,9,10,11-six hydrogen)-1,6,6-tetramethyl--10,11-dioxo phenanthro-[1,2-b] furans-2-base-)]-2-butylene acid (Tan-033)
(Tan-007) (1.68g, 5mmol), 100ml benzene, propanedioic acid (1.2g, 5.2mmol), 10ml pyridine is added in reaction flask, reflux divides water, reaction 10-12 hour, removes solvent under reduced pressure, adds the aqueous sodium carbonate of 5% in residue, filter, filtrate transfers in about PH=2 with concentrated hydrochloric acid, filters, obtains target compound with silica gel column chromatography, yield 81%, ESI-MS [M
+] (m/z): 378.16.
Example 34 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-) 2-methyl acrylate (Tan-034)
Reaction, with example 15, replaces Tan-013 with Tan-033, obtains target product, yield 79%, ESI-MS [M
+] (m/z): 392.17.
Example 35 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-) 2-ethyl propenoate (Tan-035)
Reaction, with example 15, replaces Tan-013 with Tan-033, and dehydrated alcohol replaces anhydrous methanol, obtains target product, yield 75%, ESI-MS [M
+] (m/z): 406.19.
Example 36 3-[(6,7,8,9,10,11-six hydrogen)-1,6,6-tetramethyl--10,11-dioxo phenanthro-[1,2-b] furans-2-base-)]-2-butylene acid sodium (Tan-036)
Tan-033(300mg, 0.81mmol is added in reaction flask) be dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product, yield 86%, ESI-MS [M
+] (m/z): 400.15.
The present invention utilizes the growth-inhibiting effect to the male hormone dependency Human Prostate Cancer Cells LNCaP of male sex hormone induction and the androgen independence Human Prostate Cancer Cells CWR22RV1 cell of Steroid-Resistance, measures the biologic activity of compound.
Compound biological activity determination
We check above-claimed cpd on the bioactive impact of androgen receptor with prostate cancer cell, and our cell has two kinds: LNCaP and CWR22RV1.LNCaP cell is male hormone dependency Human Prostate Cancer Cells, and CWR22RV1 is the androgen independence Human Prostate Cancer Cells of Steroid-Resistance.These two kinds of cells all express androgen receptor, and male sex hormone can induce the genetic expression of prostate specific antigen (PSA), and can induce the growth of this cell.The growth-inhibiting effect of cell, measures the biologic activity of compound.
Specific antigens is an important indicator of prostate cancer, and its expression is regulated and controled by androgen receptor, because of the physiologically active of the expression level reflection androgen receptor of a little prostate specific antigen.In order to check above-claimed cpd to the rejection ability of androgen receptor function, we effectively induce the expression of prostate specific antigen with male hormone DHT, then measure the rejection ability that compound is expressed the prostate specific antigen that DHT induces.We use the RPMI-1640 substratum (100 units/ml penicillin containing 10% foetal calf serum, 100mg/L Streptomycin sulphate and 10% foetal calf serum) cultivate prostate cancer cell LNCaP and CWR22RV1, before test compounds suppresses androgen receptor ability, I falls in the RPMI-1640 substratum of androgenic foetal calf serum (Charcoal-strippedFBS) to cultivate in containing 10% through wood charcoal adsorption at these two kinds of cell cultures of people, after two days, we add the DHT and 0.25 of androgenous 11 0nM in nutrient solution, 0.5, 1, 2, 5, 10 μMs, the test compounds of concentration tonsure, cultivate after four days, we are secreted into the concentration of the prostate specific antigen of nutrient solution with integrated enzyme reaction reagent measuring, then rejection ability (the IC that test compounds suppresses 50 percent of prostate specific antigen is calculated
50).Table 1 list tested compound to 50 percent of the prostate specific antigen of the androgen independence Human Prostate Cancer Cells CWR22RV1 of androgen-dependent Human Prostate Cancer Cells LNCaP and Steroid-Resistance rejection ability (IC
50).
Table 1, tested compound to 50 percent of the prostate specific antigen of the androgen independence Human Prostate Cancer Cells CWR22RV1 of androgen-dependent Human Prostate Cancer Cells LNCaP and Steroid-Resistance rejection ability (IC
50).
We also examine the growth-inhibiting effect of the androgen independence Human Prostate Cancer Cells CWR22RV1 cell of male hormone dependency Human Prostate Cancer Cells LNCaP that some compounds induce male sex hormone and Steroid-Resistance, similar with above method, we are placed on LNCaP cell and CWR22RV1 cell to fall in the RPMI-1640 substratum of androgenic foetal calf serum to cultivate after 2 days through wood charcoal adsorption containing 10%, add the test compounds of male hormone DHT and finite concentration gradient in the medium, its ultimate density is made to reach the DHT and 1 μM of 10nM, 2.5 μM, the test compounds of 5 μMs of concentration tonsures, cultivate after six days, we calculate the total cellular score of growth, the total cellular score that accompanying drawing display grows when being and deducting do not add DHT with the Growth of Cells sum of 10nMDHT induction is 100% growth, the compound of different concns is to the allometry rejection ability of the androgen independence human prostata cancer CWR22RV1 cell of male hormone dependency Human Prostate Cancer Cells LNCaP and Steroid-Resistance, three kinds of chemical structures are strong to the widely used bicalutamide of the growth-inhibiting energy force rate (Bicalutamide) of LNCaP and CWR22RV1.
Accompanying drawing, the allometry rejection ability of the androgen independence Human Prostate Cancer Cells CWR22RV1 (Fig. 2) of the male hormone dependency Human Prostate Cancer Cells LNCaP (Fig. 1) that three kinds of compounds are induced male sex hormone and Steroid-Resistance.
LNCaP and CWR22RV1 cell cultures is in falling in the RPMI-1640 substratum of androgenic foetal calf serum to cultivate after 2 days through wood charcoal adsorption containing 10%, add the test compounds of male hormone DHT and finite concentration gradient in the medium, its ultimate density is made to be the DHT and 1 μM of 10nM, 2.5 μM, the test compounds of 5 μMs of concentration tonsures, cultivate after six days, we calculate the total cellular score of growth, and the total cellular score grown when accompanying drawing display is and deducts do not add DHT with the Growth of Cells sum of 10nMDHT induction is the 100% allometry rejection ability carrying out computerized compound.
Claims (10)
1. the application of tanshinone compound in the medicine of preparation treatment prostate cancer, it is characterized in that, described tanshinone compound is:
6,6-dimethyl-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-1-formaldehyde;1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid;
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium formiate; 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium acetate; 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium Propionate; 1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium propanecarboxylate; 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-vinylformic acid; 3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-sodium acrylate; The acid of 3-[(6,7,8,9,10,11-six hydrogen)-1,6,6-tetramethyl--10,11-dioxo phenanthro-[1,2-b] furans-2-base-)]-2-butylene.
2. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
In reaction flask, add 200mg and 0.68mmol tanshinone IIA, 225mg and 2.03mmol tin anhydride, 25ml dioxane, heating reflux reaction 10-12 hour, filter, concentrated, obtain target compound 6,6-dimethyl-6 with silica gel column chromatography, 7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-1-formaldehyde, yield 33%
1 h-NMR (300MHz, (CDCl
3)), δ: 10.33 (s, 1H), 8.01 (d, J=7.5Hz, 1H), 7.69 (d, J=7.5Hz, 1H), 3.23 (m, 2H), 1.76-1.88 (m, 2H), 1.63-1.73 (m, 2H), 1.32 (s, 6H).
3. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
258mg and 0.8mmol1 is added in reaction flask, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furans-2-formaldehyde, 40ml acetone, 15mg Tetrabutyl amonium bromide, less than 0 DEG C is cooled to ice-water bath, drip the potassium permanganate solution 15ml that concentration is 5%, at room temperature react 15-20 hour, solids removed by filtration, filtrate regulates PH=2 with hydrochloric acid, precipitation is had to generate, filter, dry, target compound 1 is obtained with silica gel column chromatography, 6, 6-trimethylammonium-6, 7, 8, 9, 10, 11-six hydrogen-10, 11-dioxo phenanthro-[1, 2-b] furyl-2-formic acid, yield 46%,
1h-NMR (400MHz, (CDCl
3)), δ: 9.89 (s, 1H), 7.99 (d, J=7.8Hz, 1H), 7.67 (d, J=7.8HZ, 1H), 2.97 (t, 7.8HZ, 7.8Hz, 2H), 2.68 (s, 3H), 2.11 (t, J=7.8HZ, 7.8HZ, 2H), 1.81 (m, 2H), 1.37 (s, 6H).
4. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
300mg and 0.89mmol1 is added, 6,6-trimethylammonium-6,7,8 in reaction flask, 9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-formic acid is dissolved in dehydrated alcohol, and add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium formiate, yield 91%, ESI-MS [M
+] (m/z): 360.14.
5. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
300mg and 0.85mmol1 is added, 6,6-trimethylammonium-6,7,8 in reaction flask, 9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-acetic acid is dissolved in dehydrated alcohol, and add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-sodium acetate, yield 89%, ESI-MS [M
+] (m/z): 374.11.
6. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
300mg and 0.82mmol is added in reaction flask
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-ethyl propionatebe dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium Propionate, yield 88%, ESI-MS [M
+] (m/z): 388.13.
7. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
300mg and 0.79mmol is added in reaction flask
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-butyric acidbe dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product
1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furyl-2-Sodium propanecarboxylate, yield 89%, ESI-MS [M
+] (m/z): 402.14.
8. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
1.47g and 5mmol1 is added, 6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans-2-formaldehyde in reaction flask
, 100ml benzene, 1.2g and 5.2mmol propanedioic acid, 10ml pyridine, reflux divides water, reaction 10-12 hour, remove solvent under reduced pressure, in residue, add the aqueous sodium carbonate of 5%, filter, filtrate transfers in about PH=2 with concentrated hydrochloric acid, filters, obtains target compound with silica gel column chromatography
3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-vinylformic acid, yield 76%; 1H-NMR (300MHz, (DMSO-d
6), δ: 12.56 (s, 1H), 7.78-7.85 (m, 2H), 7.51 (d, 1H), 6.46 (d, 1H), 3.09 (m, 2H), 1.73 (m, 2H), 1.73 (m, 2H), 1.64 (m, 2H), 2.37 (s, 3H), 1.28 (s, 6H).
9. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
300mg and 0.83mmol is added in reaction flask
3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-vinylformic acidbe dissolved in dehydrated alcohol, add 10% alcohol sodium solution of equivalent, namely have solid to separate out, filter to obtain target product
3-(6,7,8,9,10,11-six hydrogen)-1,6,6-trimethylammonium-10,11-dioxo phenanthro-[1,2-b] furans-2-base-2-sodium acrylate, yield 81%, ESI-MS [M
+] (m/z): 386.11.
10. the preparation method of tanshinone compound, is characterized in that carrying out in accordance with the following steps:
1.68g and 5mmol2-ethanoyl-1,6,6-trimethylammonium-6,7,8,9,10,11-six hydrogen-10,11-dioxo phenanthro-[1,2-b] furans is added in reaction flask
, 100ml benzene, 1.2g and 5.2mmol propanedioic acid, 10ml pyridine, reflux divides water, reaction 10-12 hour, remove solvent under reduced pressure, in residue, add the aqueous sodium carbonate of 5%, filter, filtrate transfers in about PH=2 with concentrated hydrochloric acid, filters, obtains target compound with silica gel column chromatography
the acid of 3-[(6,7,8,9,10,11-six hydrogen)-1,6,6-tetramethyl--10,11-dioxo phenanthro-[1,2-b] furans-2-base-)]-2-butylene, yield 81%, ESI-MS [M
+] (m/z): 378.16.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310075156.1A CN103193860B (en) | 2013-03-11 | 2013-03-11 | Tanshinone compound, preparation method and its usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310075156.1A CN103193860B (en) | 2013-03-11 | 2013-03-11 | Tanshinone compound, preparation method and its usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103193860A CN103193860A (en) | 2013-07-10 |
| CN103193860B true CN103193860B (en) | 2016-01-27 |
Family
ID=48716692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310075156.1A Active CN103193860B (en) | 2013-03-11 | 2013-03-11 | Tanshinone compound, preparation method and its usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103193860B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810593A (en) * | 2016-12-26 | 2017-06-09 | 郑州大学 | A kind of bit esterified derivative of tanshinone compound 17 and its preparation technology and application |
| CN106831934A (en) * | 2016-12-26 | 2017-06-13 | 郑州大学 | A kind of 15 amide derivatives of tanshinone compound and its preparation technology and application |
| CN107698652A (en) * | 2017-09-28 | 2018-02-16 | 中山大学 | A kind of indoleamine 2 containing tanshinone compound, 3 dioxygenase inhibitors |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105037427B (en) * | 2015-06-22 | 2017-05-31 | 石家庄学院 | Tanshinone IIA ethylenimine phosphate derivative and preparation method and application |
| CN105037484B (en) * | 2015-06-22 | 2016-09-28 | 石家庄学院 | A kind of tanshinone ⅡA derivant containing polyethylene glycol groups and preparation thereof and application |
| CN105837538B (en) * | 2016-03-28 | 2018-10-23 | 中国药科大学 | Application of the tanshinone IIA derivative in preparing endothelial cell protection drug |
| CN106243071A (en) * | 2016-07-15 | 2016-12-21 | 中国人民解放军第四军医大学 | New derivatives of tanshinone IIA and its preparation method and application |
| CN109824753B (en) * | 2018-11-20 | 2021-11-26 | 中国科学院昆明植物研究所 | Tanshinone IIA derivative with IDO/TDO double-selective inhibitory activity |
| KR102343372B1 (en) * | 2019-12-17 | 2021-12-24 | (주)셀로스바이오텍 | Pharmaceutical composition for preventing or treating alopecia |
| CN113171378A (en) * | 2021-04-30 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Stem cell exosome preparation for preventing and treating male sexual dysfunction |
| CN113773289B (en) * | 2021-09-15 | 2023-05-12 | 沈阳药科大学 | Naphthalene [1,2-b ] heterocycle-4, 5-diketone compound and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101274925A (en) * | 2007-03-29 | 2008-10-01 | 中国科学院上海药物研究所 | Naphthofurans ortho-quinone compound, preparation and use thereof |
| CN102603861A (en) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | Tanshinone derivatives, medicine compositions thereof, and purposes thereof in medicine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102127037A (en) * | 2011-01-11 | 2011-07-20 | 上海交通大学 | Tanshinone compounds and applications thereof |
-
2013
- 2013-03-11 CN CN201310075156.1A patent/CN103193860B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101274925A (en) * | 2007-03-29 | 2008-10-01 | 中国科学院上海药物研究所 | Naphthofurans ortho-quinone compound, preparation and use thereof |
| CN102603861A (en) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | Tanshinone derivatives, medicine compositions thereof, and purposes thereof in medicine |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810593A (en) * | 2016-12-26 | 2017-06-09 | 郑州大学 | A kind of bit esterified derivative of tanshinone compound 17 and its preparation technology and application |
| CN106831934A (en) * | 2016-12-26 | 2017-06-13 | 郑州大学 | A kind of 15 amide derivatives of tanshinone compound and its preparation technology and application |
| CN106831934B (en) * | 2016-12-26 | 2018-09-21 | 郑州大学 | A kind of 15 amide derivatives of tanshinone compound and its preparation process and application |
| CN106810593B (en) * | 2016-12-26 | 2018-12-04 | 郑州大学 | A kind of tanshinone compound 17-position ester derivative and its preparation process and application |
| CN107698652A (en) * | 2017-09-28 | 2018-02-16 | 中山大学 | A kind of indoleamine 2 containing tanshinone compound, 3 dioxygenase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103193860A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103193860B (en) | Tanshinone compound, preparation method and its usage | |
| CN101091705B (en) | Application of compounds in isorhodanic ester classes for treating diseases of prostate and skin cancer | |
| WO2009129372A1 (en) | Compounds and methods for treating estrogen receptor-related diseases | |
| CN101720223B (en) | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions | |
| CN107921147A (en) | A kind of new precursor miRNA and its application in oncotherapy | |
| CN103417556A (en) | Applications of stilbene compounds | |
| CN102283828B (en) | Application of tetrahydroxybenzopyrone compound | |
| CN106699771A (en) | Cryptotanshinone compound, as well as preparation method and application thereof | |
| WO2017092230A1 (en) | Biflavone compound and uses thereof for treating cancers and preparing drugs | |
| CN107669686B (en) | Application of the calycosin derivative in preparation treatment ER negative breast cancer drug | |
| CN104016957A (en) | 7-methyl-3-geranyl flavone and 7-methyl-3-isopentene group flavone as well as preparation method and application thereof | |
| CN107496428B (en) | Calycosin derivative promotes the application in endothelial cell proliferation drug in preparation | |
| CN104003966B (en) | 5,7,2,, 4,-tetrahydroxy-3-ylflavone analogs and their preparation method and application | |
| CN103232521A (en) | Tanshinone imidazole compound and its preparation method and use | |
| CN110143890A (en) | A kind of chalcone derivative and synthetic method and its preparing the application in anti-nonalcoholic steatohepatitis drug | |
| CN103408597B (en) | A kind of Aromatic ruthenium complex and synthetic method thereof | |
| CN103044377B (en) | Compounds and composition with effects of inhibiting xanthine oxidase and reducing uric acid | |
| CN105085391B (en) | Cyclopropyl unsaturated quionoline compound and application as LTRA | |
| CN107056877B (en) | A kind of steroid compound and application thereof | |
| Cao et al. | Anti‐Inflammatory Effects of Gynura procumbens on RAW264. 7 Cells via Regulation of the PI3K/Akt and MAPK Signaling Pathways | |
| CN102285948B (en) | 4-hydroxy-benzopyranone derivates and application thereof | |
| CN101333237B (en) | Oligonucleotide with breast carcinoma treating function | |
| CN1321105C (en) | Derivative in hydroxy anthraquinones category and application | |
| CN114081879B (en) | New medical application of safflower Xiaoyao preparation monomer active ingredient | |
| CN107485613B (en) | Calycosin derivative treats the application in cerebral ischemia re-pouring injured drug in preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200708 Address after: 445400 Dongcheng Street Office, Lichuan City, Enshi Tujia and Miao Autonomous Prefecture, Hubei Province (Fourth Floor, Furen Home Building, Office Building of Management Committee of Lichuan Economic and Technological Development Zone) Patentee after: Lichuan Changda Industrial Technology Research Institute Co.,Ltd. Address before: Gehu Lake Road Wujin District 213164 Jiangsu city of Changzhou province No. 1 Patentee before: CHANGZHOU University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240124 Address after: 445800 Industrial Zone, Taiping Town, Hefeng County, Enshi Tujia and Miao Autonomous Prefecture, Hubei Province Patentee after: Chu Xingtang Food (Enshizhou) Co.,Ltd. Country or region after: China Address before: 445400 Dongcheng sub district office of Lichuan City, Enshi Tujia and Miao Autonomous Prefecture, Hubei Province Patentee before: Lichuan Changda Industrial Technology Research Institute Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |